NCT05484674 is a NA clinical trial of Deroofing and laser in Hidradenitis Suppurativa, sponsored by University of Texas at Austin.

Who is sponsoring NCT05484674?

NCT05484674 is sponsored by University of Texas at Austin.

What drugs are being tested in NCT05484674?

Interventions in NCT05484674: Deroofing and laser.

What condition does NCT05484674 study?

NCT05484674 studies Hidradenitis Suppurativa.

Is NCT05484674 still recruiting?

NCT05484674 is currently status unknown. Last updated 2 August 2022.

Last reviewed 2022-08-02 · How we verify

NCT05484674

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Control of Hidradenitis Suppurativa of the Underarms After Combination Deroofing and Laser

Status unknown NA Last updated 2 August 2022

What this trial tests

NA trial testing Deroofing and laser in Hidradenitis Suppurativa in 6 participants. Status unknown.

Timeline

6 August 2022

Primary endpoint
6 August 2023

6 December 2023

Quick facts

Lead sponsor	University of Texas at Austin
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	6 August 2022
Primary completion	6 August 2023
Estimated completion	6 December 2023

Drugs / interventions tested

Deroofing and laser

Conditions studied

Hidradenitis Suppurativa — all drugs for Hidradenitis Suppurativa →

Sponsor

University of Texas at Austin

Who can join

18 and older, any sex, with Hidradenitis Suppurativa. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to determine whether a series of laser hair removal treatments can improve participant outcomes after deroofing procedures. A deroofing procedure is a surgery where larger hidradenitis suppurativa bumps (called nodules) and hidradenitis suppurativa tunnels (called sinus tracts) are removed and left to heal open without stitches.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa-Part II: Procedural and Wound Care Therapies.
Fragoso NM, Masson R, Gillenwater TJ, Shi VY, et al · · 2023 · cited 3× · PMID 37402030 · DOI 10.1007/s13555-023-00957-5

Verify or expand the search:

Other recruiting trials for Hidradenitis Suppurativa

Currently open trials in the same condition.

NCT07244263 — A Study of Zasocitinib in Adults With Hidradenitis Suppurativa · Phase 2 · recruiting
NCT07225569 — A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Sup · Phase 2 · recruiting
NCT07243782 — Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cose · recruiting
NCT07282015 — Real-world Secukinumab Outcomes in Canadian HS Patients · recruiting
NCT07228390 — A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps · Phase 2 · recruiting

Other University of Texas at Austin trials

Trials by the same sponsor.

NCT07319234 — Development of MENU Protocol · NA · not yet recruiting
NCT07480109 — Increased Dietary Protein Intake During GLP-1 Medication Use (in Middle-aged Women With Overweight/Obesity) · NA · not yet recruiting
NCT07069413 — Sibwatch: Optimizing Intervention Options for Infants and Toddler Siblings of Autistic Children · NA · not yet recruiting
NCT07370311 — A Culturally Adapted Decision Aid Intervention to Support Chinese American Dementia Caregivers in Feeding-Related Decisi · NA · not yet recruiting
NCT07441122 — Enhancing Attention in Elderly Using a Brain-Computer-Interface · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05484674 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Texas at Austin
Last refreshed: 2 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05484674.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing